Cell Therapeutics, Inc. announced that it has voluntarily withdrawn its New Drug Application ('NDA') for Pixuvri (pixantrone) for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma ('NHL') in patients who failed two or more lines of prior therapy. The NDA was withdrawn because, after communications with the U.S. Food and Drug Administration ('FDA'), the company needed additional time to prepare for the review of the Pixuvri NDA by the FDA's Oncologic Drugs Advisory Committee at its February 9, 2012 meeting. Prior to withdrawing the NDA, the company requested that the FDA consider rescheduling the review of the Pixuvri NDA to the ODAC meeting to be held in late March. The FDA was unable to accommodate the company's request to reschedule, and given the April 24, 2012 Prescription Drug User Fee Act ('PDUFA') date, the only way to have Pixuvri possibly considered at a later ODAC meeting was for the company to withdraw and later resubmit the NDA. The company plans to resubmit the NDA in 2012.